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ABSTRACT OF DISSERTATION

SUPERNATANT PROTEIN FACTOR: INSIGHTS INTO ITS REGULATION
AND ABILITY TO STIMULATE CHOLESTEROL SYNTHESIS IN VITRO AND IN
CELL CULTURE
Supernatant protein factor (SPF) is a 46-kDa cytosolic protein that stimulates
squalene monooxygenase, which catalyses the second committed step in cholesterol
biosynthesis. The mechanism by which SPF stimulates this enzyme is not understood
and the goal of these studies was to see if SPF affected cholesterol synthesis in
cultured cells. Rat supernatant protein factor-like protein (SPF2) shares 77% sequence
identity with human SPF.

In my studies SPF2 also stimulated squalene

monooxygenase in vitro and incubation of SPF2 with protein kinase A (PKA) and Cδ
increased its activity by about 2-fold, as shown earlier with SPF.

GTP and GDP

prevented the stimulation of squalene monooxygenase by SPF2, suggesting that
binding of these nucleotides inhibits SPF2. This inhibition could be prevented by the
addition of α-tocopherol, although α-tocopherol alone had no effect on SPF2 activity in
vitro.

Expression of human SPF in hepatoma cells, which lack expression of

endogenous SPF, increased cholesterol synthesis by 2-fold and addition of dibuytrylcAMP, a PKA activator, to these cells yielded an additional 62% increase whereas
addition of a PKA inhibitor completely blocked the ability of SPF to stimulate cholesterol
synthesis. To further confirm a role for phosphorylation in the regulation of SPF,
substitution of alanine for serine-289 (a putative PKA recognition site) reduced the
PKA-mediated activation of SPF in vitro by 50%, as measured with microsomal

squalene monooxygenase and completely blocked the ability of SPF to stimulate
cholesterol synthesis in hepatoma cells.

In further structure-function studies,

deletion of the carboxy-terminal Golgi-dynamics domain greatly increased the ability
of SPF to stimulate squalene monooxygenase in microsomes, but, paradoxically
prevented SPF from stimulating cholesterol synthesis in cell culture. Addition of
brefeldin A, which disrupts Golgi formation, also abolished the ability of SPF to
stimulate cholesterol synthesis, supporting a role for the Golgi in SPF function.
Since squalene monooxygenase is not thought to be rate-limiting with regard to
cholesterol synthesis, the possibility that SPF might stimulate other enzymes in the
cholesterol biosynthetic pathway was investigated.
mevalonate for

14

The substitution of

14

C-

C-acetate completely blocked an SPF-induced 1.5-fold increase in

squalene synthesis, suggesting that SPF stimulated mevalonate synthesis at HMGCoA reductase.

2,3-Oxidosqualene synthesis from

14

C-mevalonate remained

elevated (1.3-fold) with mevalonate demonstrating that SPF also stimulated
squalene monooxygenase in hepatoma cells.

SPF did not increase HMG-CoA

reductase or squalene monooxygenase enzyme levels in cells, indicating that SPF
directly activated these enzymes. Indeed, addition of purified recombinant SPF to
rat liver microsomes stimulated HMG-CoA reductase by about 1.5-fold.

These

results reveal that SPF directly stimulates HMG-CoA reductase, the rate-limiting
step of the cholesterol biosynthetic pathway, as well as squalene monooxygenase,
and, coupled with the ability of PKA-mediated phosphorylation to regulate SPF
activity, suggest a new means by which cholesterol synthesis can be rapidly
modulated in response to hormonal and environmental signals.
Key words:
Supernatant protein factor, cholesterol
monooxygenase, phosphorylation, protein kinase A.
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CHAPTER ONE
BACKGROUND

Squalene Monooxygenase
The biosynthetic pathway for cholesterol from acetate is relatively well
characterized (Figure 1.1), although its regulation beyond HMG-CoA reductase is
relatively unknown despite its importance in mammalian physiology. An increase in
serum cholesterol levels in humans is associated with the development of
cardiovascular diseases. Despite the bad reputation of cholesterol, it is essential for a
number of physiological processes, including the maintenance membrane integrity, the
production of bile acids, and the formation of steroid hormones.

The synthesis of

squalene, a key intermediate, requires five steps and is often referred to as the
mevalonate, or the isoprenoid synthesis pathway. This pathway also yields geranyl
pyrophosphate which in turn yields geranylgeranylated proteins like Rab and Rho and
farnesyl pyrophosphate, as well as ubiquinone, dolichol, HEME a and farnesylated
proteins like Ras. These proteins are essential for a variety of cell functions such as
vasoconstriction, apoptosis, and immune function.

Squalene monooxygenase

catalyzes the second step in this committed pathway for cholesterol synthesis. This
pathway yields only cholesterol in animal somatic cells, ergosterol in yeast, and
phytosterols in plants.

Squalene monooxygenase is common to all sterol synthesis

pathways and catalyzes the epoxidation of squalene to 2,3-oxidosqualene, which is also
the first oxygenation step in the sterol biosynthetic pathway.
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Figure 1.1 Cholesterol biosynthetic pathway.
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Cholesterol

Biochemistry and Molecular Biology of Squalene Monooxygenase
Squalene monooxygenase (EC 1.14.99.7; earlier called squalene epoxidase) is a
64-kDa flavin adenine dinucleotide (FAD)-containing enzyme bound to the endoplasmic
reticulum of eukaryotic cells. The enzyme catalyzes the epoxidation of squalene across
a C=C double bond utilizing NADPH and oxygen to yield 2,3-oxidosqualene (Yamamoto
and Bloch 1970).

Squalene monooxygenase resembles cytochrome P450 in its

reaction chemistry and is dependant upon NADPH- cytochrome P450 reductase for
reducing equivalents (Ono, Takahashi et al. 1980). Squalene monooxygenase is not a
P450: Squalene monooxygenase is not inhibited by typical P450 inhibitors like carbon
monoxide and metyrapone.

In addition, it also shows no absorption at 450 nm

(Yamamoto and Bloch 1970; Ono and Bloch 1975).
Squalene monooxygenase requires NADPH- cytochrome P450 reductase (CPR)
for its activity. CPR is responsible for the transfer of electrons from NADPH to a variety
of enzymes, chiefly the cytochromes P450. CPR is a flavin containing enzyme, like
squalene monooxygenase, having one molecule of FAD and FMN. The FAD of CPR
accepts two electrons from NADPH in the form of a hydride ion. The electrons are then
transferred in sequential fashion to the FMN before being donated to CPR’s redox
partner, in this case squalene monooxygenase.

In the squalene monooxygenase

system the two electrons move from CPR to the FAD in squalene monooxygenase and
are used to reduce one atom of molecular oxygen to water. The other oxygen atom is
then inserted across the double bond (C=C) to form the product 2,3-oxidosqualene.
In addition to CPR and NADPH, squalene monooxygenase requires a
microsomal supernatant component.

The

supernatant requirement was found to

consist of three different components: a soluble protein called supernatant protein factor
(SPF), phospholipids, and FAD (Tai and Bloch 1972). Ono and Bloch in 1975 published
that supernatant protein factor could be replaced by the non-ionic detergent Triton X100, and that this detergent stimulated the squalene monooxygenase reaction. SPF
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has no effect in the presence of this detergent, suggesting that SPF requires an intact
membrane for activity.
Regulation of Squalene Monooxygenase
The enzyme squalene monooxygenase is considered a important enzyme in the
cholesterol biosynthetic pathway because of its low specific activity; lower than that of 3hydroxy-3methylglutaryl CoA reductase (HMGR) and squalene synthase (Sakakibara,
Watanabe et al. 1995). This suggests that squalene monooxygenase might be the ratelimiting step in the cholesterol biosynthetic pathway and thus an important regulatory
point; indeed oxysterols and low density lipoproteins (LDLs) have been shown to
decrease squalene monooxygenase activity in cultured hepatoma cells apotential form
of feedback regulation (Hidaka, Satoh et al. 1990). The same authors also reported that
the inhibition of HMG-CoA reductase, which is the initial regulatory enzyme for the
cholesterol biosynthetic pathway, increased squalene monooxygenase activity (Hidaka,
Satoh et al. 1990). Similar data was also obtained from animal studies (Satoh, Hidaka
et al. 1990). It was also discovered that inhibition of squalene monooxygenase by NB598 (a specific inhibitor of squalene monooxygenase) resulted in a decrease in
secretion of cholesterol, triacylglycerol, and apolipoprotein B from HepG2 cells (Horie,
Hayashi et al. 1993). Recent DNA micro-array expression analysis has also revealed
that squalene monooxygenase was one of the enzymes in the cholesterol biosynthetic
pathway, along with HMG-CoA reductase, whose expression was suppressed in human
fibroblasts within 4h after serum addition (Iyer, Eisen et al. 1999). Recent evidence also
points to the fact that the squalene monooxygenase gene has a sterol response
element (SRE) site and a site for another ubiquitous factor called nuclear factor Y (NFY) present in its promoter element. This adds to the growing evidence that suggests
that the gene for squalene monooxygenase is under the control of sterol response
element-binding protein (SREBP) and that this factor can regulate its expression. Since
this enzyme is a major player in the post-squalene pathway, it has evoked considerable
interest as a therapeutic target for lowering low-density lipoprotein (LDL) cholesterol,
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which is a high risk factor in cardiovascular disease and especially coronary heart
disease.
Supernatant Protein Factor (SPF)
The properties of squalene monooxygenase have been studied extensively by
Bloch and colleagues with the use of rat liver microsomes. In 1957 they reported that
microsomal squalene monooxygenase activity was increased by addition of rat liver
105000xg supernatant (Tchen and Bloch 1957). They later went on to show that the
supernatant fraction contributes both a heat-labile protein and heat-stable small
molecules for the monooxygenase system (Yamamoto and Bloch 1970). Around 1970
the heat stable factors were identified as being FAD, phosphatidylserine and
phosphatidylglycerol, while the heat-labile factor was shown to be a 47 kDa protein
which was trypsin-sensitive; this protein was purified by a factor of 11000 and called
“supernatant protein factor” (SPF) (Tai and Bloch 1972). These same researchers also
noted that SPF would not stimulate squalene monooxygenase when it was solubilized
and partially purified; this suggested that SPF is effective only with the microsomal
enzyme.

Bloch and colleagues also demonstrated that SPF promoted transfer of

squalene across membranes in vitro, which led to the hypothesis that SPF facilitates the
access of a hydrophobic substrate, in this case squalene, to a site on squalene
monooxygenase (Friedlander, Caras et al. 1980). All the above observations suggested
that SPF could possibly play a role in cholesterol biosynthesis or homeostasis in vivo.
Supernatant protein factor also activates the second enzyme in the pathway from
squalene to lanosterol, oxidosqualene cyclase (Caras and Bloch 1979). The activation
conditions for this enzyme differ from those of squalene monooxygenase in that the
phospholipids can be substituted by phosphatidylethanolamine (Caras and Bloch 1979).
Oxidosqualene cyclase is suggested to be associated with the luminal surface of the
microsomal membrane and thus is not directly associated with the cytosol or SPF. The
above findings supported the argument that SPF may facilitate the transfer of squalene
and oxidosqualene between membrane compartments. SPF has not been shown to
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activate any of the other downstream enzymes in the cholesterol pathway, suggesting
that it is specific for the squalene-to-lanosterol steps. The enzymes activated by SPF
are shown in Figure 1.2.
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Figure 1.2 Enzymes stimulated by SPF.
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SPF and Lipid Transfer Proteins
Studies on SPF have been dormant for the last two decades, and no information
was forthcoming till 2001. Shibata et al. in 2001 cloned cDNAs for rat and human SPF
(Shibata, Arita et al. 2001). Both rat and human SPF cDNAs encoded a 403 amino
acid, 47 kDa protein. Rat and human SPF share 94% sequence identity and are
abundantly expressed in the liver and intestine (Shibata, Arita et al. 2001). Comparison
of SPF to the BLAST and protein database suggested that SPF belonged to a family of
lipid binding/transfer proteins (Figure 1.3).

SPF shows significant homology to α-

tocopherol transfer protein, cellular retinal-binding protein and yeast sec14p. Exact roles
of all these proteins are nebulous.

Sec14p is a yeast protein which exhibits

phosphatidylinositol/phosphatidylcholine transfer activity and is required for protein
secretion through the Golgi complex. Cellular retinal-binding protein is involved in the
binding of 11-cis-retinal in the mammalian visual system, and α-tocopherol transfer
protein (α-TTP) specifically binds α-tocopherol (vitamin E) and is thought to be involved
in regulating serum vitamin E levels. All of these proteins contain a 185-amino acid
CRAL/TRIO domain and it is this domain, which seems to be involved in the lipid
binding.

SPF in addition contains a 157-amino acid extension on the C-terminus

(Figure 1.3), which may bind GTP. Two segments of SPF, between 34-48 and 206-209
are especially highly conserved in this group of proteins. The region between these
amino acids is probably the ligand-binding domain. SPF surprisingly also shows 77%
identity to a protein isolated from rat olfactory epithelium (Merkulova, Andreeva et al.
1999). This SPF-like protein binds GTP and was identified on the basis of a GTPbinding domain at the beginning of the C-terminus. SPF also shares the same GTPbinding motif as mentioned above. The role of this olfactory SPF-like protein and its
relation to cholesterol in the olfactory epithelium remains a mystery. Panagabko et al.
showed that human SPF had the highest affinity for phosphatidylinositol relative to
phospholipids and other related compounds (Panagabko, Morley et al. 2003).
addition

Stocker

et

al.

have

also

shown

that

SPF

binds

to

In

RRR-alpha-

tocopherylquinone, the major physiological oxidation product of RRR-alpha-tocopherol
(Stocker and Baumann 2003).
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Crystal Structure of Human SPF
In 2002 Stocker et al. published the crystal structure of supernatant protein
factor. The structure of SPF consists of 13 β-strands, 11 α-helices, and 8 310-helices.
This structure bears similarity to the yeast Sec14p protein. SPF folds into two domains:
the N-terminal domain consists of 275 residues which form a Sec14-like domain and the
C-terminal 115 residues form a eight stranded jelly-roll “barrel” (Stocker, Tomizaki et al.
2002). The central β sheet in the N-terminal domain forms one side and helices 6-10 on
the other side enclose a large hydrophobic ligand binding pocket. The entrance to the
ligand-binding pocket is blocked by the helices 9-10 and a connecting loop. The Cterminal residues 290-403 fold into an eight stranded anti-parallel β sandwich consisting
of two four-stranded anti-parallel β sheets.

The exact function of this domain is

unknown but has been suggested to bind to cell membranes (Anantharaman and
Aravind 2002). The representative crystal structure of SPF along with its various
domains and ligand is shown in Figure 1.4.
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Figure 1.4 Crystal structure of human SPF
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SPF and the GOLD-Domain
The carboxyl-terminal domain of SPF (amino acids 290 to 403) shows
sequence similarity to proteins involved in Golgi function, including the p24 family,
which are involved in coated vesicle transport from the endoplasmic reticulum to
Golgi (Anantharaman and Aravind 2002). This domain is not found in other lipid
transfer proteins in the CRAL/TRIO family, including Sec14p and α-tocopherol
transfer protein. This domain is called the GOLD (Golgi dynamics) domain. The
GOLD-domain proteins can be divided into two categories; Category 1 wherein the
proteins are anchored in the membrane by a membrane spanning helix, and
category 2, wherein the GOLD-domain occurs at the extreme carboxyl or amino
terminus, along with other domains that are known to interact with lipid membranes.
SPF belongs to the second category.

The same authors suggest that SPF and

SPF-like proteins could function as double-headed adaptors or vesicular cargoloading molecules and interact with specific proteins as well as lipid membranes.
The exact role of this domain in SPF remains to be determined.
SPF and Tocopherol Associated Protein (TAP)
In 2000 Zimmer et al. described the identification, molecular cloning, and in vitro
expression of human tocopherol associated protein (TAP). They described this protein
to be a part of the ligand-binding proteins which have a CRAL motif in common. The
proposed role of this protein was that it was a vitamin E binding protein. This binding
protein would hypothetically function to transfer α-tocopherol from chylomicrons via liver
into blood plasma (Zimmer, Stocker et al. 2000). Surprisingly, the protein described as
TAP has the same amino-acid sequence as SPF. Though the exact functions of TAP
have not yet been determined, latest evidence has suggested that TAP is a liganddependent transcriptional activator (Yamauchi, Iwamoto et al. 2001).

TAP binds to

binds to the biotinylated form of α-tocopherol with a KD of 0.46 µM. Other forms of
vitamin E show much less affinity for TAP (Yamauchi, Iwamoto et al. 2001). TAP fused
with a green fluorescent protein (GFP), was shown to translocate from the cytosol to the
nucleus in an α-tocopherol dependent manner. Transient transfections of GAL4-DNA-
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binding domain/TAP fusion protein activates the GAL-dependent luciferase gene in an
α-tocopherol dependent manner (Yamauchi, Iwamoto et al. 2001). All the above results
suggest that TAP (SPF) is a transcription factor.
SPF, Gene Transcription, and Cholesterol Synthesis
From the data present in the literature it is clear that SPF increases the activation
of squalene monooxygenase in vitro, and it has been postulated that SPF transfers
squalene into, within, or between membranes. However, high-affinity squalene binding
has not been demonstrated. SPF increases cholesterol biosynthesis when expressed
in hepatoma cells (Shibata, Arita et al. 2001). Nagai et al. have also demonstrated that
SREBP-2 and NF-Y are involved in the transcriptional regulation of squalene
monooxygenase (Nagai, Sakakibara et al. 2002).

It is possible that SPF is a

transcription factor involved at some level in the cholesterol biosynthetic pathway. This
could be due to direct activation of the gene for squalene monooxygenase, or it could
be via the sterol response element-binding proteins (SREBPs), especially SREBP-2,
which appears to be involved in the transcriptional regulation of squalene
monooxygenase.
enzymes

in

the

There is also the possibility that SPF could be activating other
cholesterol

biosynthetic

pathway

in

monooxygenase.

Copyright © Vishwesh Mokashi 2004
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CHAPTER 2
CLONING AND PURIFICATION OF HUMAN SUPERNATANT PROTEIN FACTOR
(hSPF)
Cloning and Expression of hSPF
The hSPF cDNA was amplified with Pfu polymerase (Stratagene) from a human
liver cDNA library (Quick-Clone, Clontech) with primers based on the reported human
SPF sequence (Shibata, Arita et al. 2001) and that incorporated an NcoI restriction site
at the translation start codon and an XhoI restriction site immediately following the stop
codon (Figure 2.1, Lane 2). The amplification product was cloned into the PCR-BLUNT
II TOPO vector (Invitrogen), plasmid DNA was isolated, and the sequence of the insert
was determined at the Molecular Structure and Analysis Facility, University of Kentucky,
to confirm identity with SPF. The SPF cDNA insert was released with NcoI and XhoI,
purified by agarose-gel electrophoresis, and cloned into the pTYB4 expression vector
(New England Biolabs). SPF protein was purified following the protocol for expression of
intein fusion proteins with the IMPACT T7 system as follows. SPF expression was
induced

in

E. coli

ER2566

cells

overnight

with

1 mM

isopropyl-β-D-

thiogalactopyranoside at 30 °C with slow shaking. All subsequent steps were carried out
at 4 °C. Cells were broken in a French pressure cell in buffer containing 20 mM Tris-HCl
(pH 7.4), 500 mM NaCl, and 0.1 mM EDTA, and the lysate was cleared by 12,000 × g
centrifugation for 30 min followed by digestion with 1 µg of DNA nuclease for 1 h. The
cleared lysate was loaded onto a chitin affinity column (2-ml bed volume), washed with
40 ml of lysis buffer, and incubated overnight at 4 °C in 4 ml of buffer containing 30 mM
β-mercaptoethanol to promote cleavage of the intein-SPF bond. SPF was eluted with
10-20 ml of the same buffer, which was then replaced by centrifugal dialysis with 20 mM
Tris-HCl, pH 7.4, and the sample was stored at

80 °C. The purified protein retains four

amino acids (Leu-Glu-Pro-Gly) at the C terminus that are derived from the intein fusion
sequence. The scheme of purification is shown in Figure 2.2.
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Figure 2.1 Agarose gel of amplified hSPF clone.
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Figure 2.2 Scheme of purification of hSPF by chitin column.
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Results
Cloning and Purification of Human SPF — The published sequence of human
SPF (Shibata, Arita et al. 2001) was used to design primers for the amplification of SPF
from a human liver cDNA library (Figure 2.1, lane 2). The resulting cDNA exhibited two
differences from the published sequence: at codon 2, where incorporation of an NcoI
site into the primer to facilitate cloning replaced a serine with glycine; and at codon
11, where a lysine was encoded instead of arginine. A lysine is also found at this latter
position in the rat sequence (Shibata, Arita et al. 2001). Expression and purification of
SPF from E. coli yielded a largely homogeneous protein that migrated at 45 kDa,
consistent with the predicted molecular mass of 47 kDa (Figure 2.3)
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Figure 2.3 SDS–polyacrylamide gel electrophoresis of bacterially expressed SPF.
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CHAPTER 3
RAT SUPERNATANT PROTEIN FACTOR-LIKE PROTEIN (SPF2)
Introduction to Rat SPF2
There are three SPF-related genes in the human genome, sharing 70–77%
identity in encoded protein sequences (GenBank Accession Nos. NP_036561,
NP_777635, and NP_777637). cDNAs corresponding to all three genes have been
cloned (Zimmer, Stocker et al. 2000; Shibata, Arita et al. 2001; Yamauchi, Iwamoto et
al. 2001; Kempna, Zingg et al. 2003; Singh, Mokashi et al. 2003), but only one has been
characterized with regard to its ability to stimulate squalene epoxidation (Singh,
Mokashi et al. 2003). This protein also corresponds to tocopherol-associated protein. In
the rat, two SPF proteins have been identified and cloned (Novoselov, Peshenko et al.
1996; Shibata, Arita et al. 2001). Whereas one corresponds to the traditional SPF
protein first characterized by Bloch and colleagues (Tai and Bloch 1972; Ferguson and
Bloch 1977; Shibata, Arita et al. 2001), the second protein, rat secretory protein, was
identified as a potential G-protein subunit based on its reactivity with an antibody to the
α-subunit of G-proteins (Merkulova, Andreeva et al. 1999). The cDNA sequence of rat
secretory protein subsequently revealed that it was not an α-subunit, although it could
be photolabeled with GTP (Merkulova, Andreeva et al. 1999). This protein is highly
expressed in epithelial tissues, including those from the olfactory bulb, trachea, lung,
and skin (Merkulova, Andreeva et al. 1999). The human homolog is expressed in lung
tissue but is less evident in skin. No function has yet been assigned to this protein.
To determine if this second rat SPF-like protein (SPF2) shared the characteristics of
SPF, we have cloned and expressed rat SPF2 in Escherichia coli and determined the
ability to stimulate squalene monooxygenase in vitro.
Experimental Methods
Cloning and expression of rat SPF2 — A cDNA to SPF2 was amplified with Pfu
polymerase (Stratagene) from a rat olfactory bulb cDNA library, provided by Dr. Xinxin
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Ding (New York State Department of Health). Primers were based on the published rat
SPF2 sequence (Merkulova, Andreeva et al. 1999), and incorporated an NdeI restriction
site at the translation start codon and an XhoI restriction site immediately after the stop
codon. The amplification product was ligated into the PCR-BLUNT II TOPO vector
(Invitrogen), plasmid DNA was prepared, and the sequence of the insert was
determined at the Molecular Structure and Analysis Facility, University of Kentucky. This
sequence confirmed its identity with the published sequence of rat SPF2 (Merkulova,
Andreeva et al. 1999), GenBank Accession No. AJ132352. The SPF2 cDNA was
released with NdeI and XhoI, purified by agarose gel electrophoresis, and ligated into
the pTYB2 expression vector (New England Biolabs). SPF2 protein was purified from E.
coli ER2566 cells following the protocol for expression of intein-fusion proteins with the
IMPACT T7 system as described previously (Singh, Mokashi et al. 2003). The purified
protein retains four amino acids (Leu–Glu–Pro–Gly) at the C-terminus, which are
derived from the intein-fusion protein sequence. The elution buffer was replaced with
20 mM Tris–HCl, pH 7.4, by centrifugal dialysis, protein was quantified with Coomassie
Plus reagent (Pierce), and the sample was stored at -80 °C.
Squalene monooxygenase activity assays — Squalene monooxygenase activity
assays were carried The microsomal fraction (100,000 × g pellet, ~15 mg of protein/ml)
and cytosolic fraction (100,000 × g supernatant, ~20 mg of protein/ml) were prepared
from the livers of untreated male Harlan Sprague-Dawley rats (~200 g) by standard
procedures. Animals were maintained on a normal light-dark cycle with free access to
rat chow and were killed in late morning by decapitation. 200 µg of microsomal protein,
30 µM FAD, 40 µM [14C]squalene, 10 µg of phosphatidylglycerol, and 0.3 mM AMO
1618 (Calbiochem) to inhibit oxidosqualene cyclase in 200 µl of 20 mM Tris-HCl buffer,
pH 7.4, with 1 mM EDTA. Reactions were started by the addition of NADPH to 1 mM,
incubated in a 37 °C water bath for 1 h, and were stopped by the addition of 0.5 ml of
10% KOH in methanol after the incubation volume was brought to 1 ml with water. The
tubes were capped, and after saponification at 80 °C for 1 h the neutral lipids were
extracted with 3 ml of petroleum ether. The solvent was removed under evaporative
centrifugation, and the lipids were resuspended in 50 µl of the same and spotted onto
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silica thin-layer plates. Lipids were fractionated in 5% ethyl acetate in hexane and
visualized and quantified by electronic autoradiography (Packard Instant Imager).
Radiolabeled squalene (14C) was synthesized by the Chemical Synthesis Facility,
Department of Medicinal Chemistry, University of Utah, at 7 mCi/mmol.
The effect of nucleotides and α-tocopherol on the ability of SPF2 to stimulate squalene
monooxygenase was determined either by preincubating 5 µg of SPF2 with 3 mM
nucleotide (ATP, GTP or GDP) or 50 µM α-tocopherol for 30 min at 37 °C, or by adding
these potential ligands directly to the SPF2/microsomal incubations at the final
concentrations indicated above. All nucleotide incubations included 4.5 mM MgCl2.
Unbound nucleotide or α-tocopherol was removed from the preincubations by
centrifugal filtration using Microcon concentrators (30 kDa cutoff) and SPF2 protein was
resuspended in 20 mM Tris buffer, pH 7.4, and added to squalene monooxygenase
reactions as described above.
Activation of SPF2 by protein kinases — The ability of protein kinases A and C
(PKA, PKC) to activate SPF2 was determined with 5 U of mouse recombinant catalytic
PKA subunit Cδ, (Calbiochem) or 0.25 U of human recombinant PKC isozyme δ,
(Calbiochem), according to the supplier's instructions. The reaction mixture for PKA
included 3mM ATP, 1mM cAMP and 200mM Tris buffer. The reaction mixture for PKCδ
consisted of 3mM ATP, activator solution containing phosphatidylserine and
diacylglycerol (3mg/ml) and 200mM Tris buffer containg 5mM calcium chloride and
100mM magnesium chloride. Each kinase was incubated with purified recombinant
SPF2 for 30 min at 30°C. Following the incubation of each kinase with recombinant
SPF2 (5 µg) at 30 °C for 30 min, the ability of each mixture to stimulate squalene
monooxygenase was determined as described above. The effect of nucleotides (3 mM
GTP or GDP) and α-tocopherol (50 µM) on the activation of SPF2 by PKA and PKCδ
was determined by adding these substances to the preincubations.
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Results
Cloning and purification of rat SPF2 — The published sequence of rat SPF2
(Merkulova, Andreeva et al. 1999) was used to design primers for the polymerase-chain
amplification of an SPF2 cDNA from a rat olfactory bulb cDNA library. The resulting
cDNA was identical to the reported sequence (GenBank Accession No. AJ132352)
(Merkulova, Andreeva et al. 1999) with the addition of four amino acids (Leu–Glu–Pro–
Gly) encoded at the C-terminus as a result of the cloning strategy. The expression and
purification of SPF2 from E. coli yielded a homogeneous protein that migrated slightly
more slowly than human SPF, consistent with its predicted molecular mass of 45 kDa
(Figure 3.1).
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Figure 3.1 SDS–polyacrylamide gel electrophoresis of bacterially expressed SPF
and SPF2. The purified proteins were loaded onto a 10% SDS–polyacrylamide gel and
after electrophoresis the gel was stained with Coomassie blue. Lane 1, SPF2, 3 µg;
lane 2, SPF, 3 µg; and lane 3, molecular mass markers in kilodalton.
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Stimulation of squalene monooxygenase by SPF2 — While SPF has long been
known to stimulate squalene monooxygenase activity in microsomal preparations, a role
for the more recently identified rat SPF2 protein has not been established. It is also
important to mention that rat SPF1 acts to stimulate squalene monooxygenase in vitro
(Shibata, Arita et al. 2001). To determine if SPF2 could also stimulate squalene
monooxygenase, increasing amounts of the purified protein, ranging from 0.01 to
1.6 µg, were added to rat liver microsomes and squalene monooxygenase activity was
determined (Figure 3.2). Maximum stimulation of monooxygenase activity was obtained
with 0.8 µg of recombinant rat SPF2 protein, a value identical to that determined for
maximal activity of recombinant human SPF (Singh, Mokashi et al. 2003). The
stimulatory effect was lost with higher concentrations of SPF2, as was also seen with
SPF (Singh, Mokashi et al. 2003). The maximal stimulation by SPF2 was only about
50% of that obtained with human SPF.
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Figure 3.2 Stimulation of microsomal squalene monooxygenase by recombinant
SPF2. Squalene monooxygenase activity in rat liver microsomes was determined over
60 min, in the absence (control) or presence of the indicated amounts of SPF2. SPF
was used at 0.8 µg. Each value represents the mean ± SE of two separate experiments
carried out in duplicate.
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Effect of various nucleotides on SPF2 — SPF2 purified from rat olfactory tissue
has been reported to bind GTP (Novoselov, Peshenko et al. 1996), and both SPF and
rat SPF2 contain a putative GTP-binding motif at the C-terminus (Porter 2003). SPF has
also been reported to bind α-tocopherol (Zimmer, Stocker et al. 2000; Yamauchi,
Iwamoto et al. 2001; Panagabko, Morley et al. 2003). To determine if nucleotides or αtocopherol affected the ability of SPF2 to stimulate squalene monooxygenase, 3 mM
ATP, GTP or GDP or 50 µM α-tocopherol was added to SPF2 preparations. GTP and
GDP prevented the stimulation of squalene monooxygenase by SPF2, suggesting that
binding of these nucleotides inhibits SPF2. This inhibition could be prevented by the
addition of α-tocopherol, although α-tocopherol alone had no effect on SPF2 activity.
These effects were seen when the putative ligands were added in preincubations and
when they were added directly to the microsomal assays (Figure 3.3). GTP and GDP
had no effect on squalene monooxygenase activity in the absence of SPF2.
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Figure 3.3 Putative SPF ligands affect SPF2 activity.

The ability of various

nucleotides (3 mM) and α-tocopherol (50 µM) to affect SPF2 activity was determined by
monitoring the ability of the treated preparations to stimulate microsomal squalene
monooxygenase activity. Each value represents the mean ± SE of two experiments
carried out in duplicate.
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bars, addition of the nucleotide or α-tocopherol (αT) directly to the microsomal assay.
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Activation of SPF2 by protein kinases — Human SPF is activated approximately
twofold by PKA and PKCδ (Singh, Mokashi et al. 2003). To determine if rat SPF2 is
similarly activated by these kinases, purified SPF2 was incubated with PKA and PKCδ
in the presence of ATP (Figure 3.4). PKA increased SPF2 activity by approximately
twofold, but PKCδ was less effective. The addition of these protein kinases to
microsomes alone did not increase squalene monooxygenase activity, indicating that
the stimulation provided by these kinases was due to an effect on SPF2. These results
suggest that rat SPF2 is activated by protein kinase A in a manner similar to that of SPF
and that this activation is presumably mediated by phosphorylation of one or more
specific serines or threonines. The addition of GTP, GDP, or α-tocopherol had no effect
on the activation of SPF2 by these kinases (data not shown).
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Figure 3.4 Activation of SPF2 by protein kinases. Purified recombinant SPF2 was
incubated in the absence or presence of the indicated protein kinases and ATP, and the
ability of the preparations to stimulate microsomal squalene monooxygenase was
determined. PKA, protein kinase A; PKCδ, protein kinase C, δ isoform; and control, no
SPF2 added. Each value represents the mean ± SE of two experiments carried out in
duplicate.
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Discussion
There are three SPF genes in human and at least two in both rat and mouse, but
the physiological role of these proteins remains controversial. Proposed functions
include shuttling squalene into and between intracellular membranes, transferring αtocopherol between compartments in the cell, activating gene transcription in response
to α-tocopherol, and modulating phosphatidylinositol-3-kinase activity. In this study we
have cloned, expressed, purified, and assigned a possible function to one of these SPFlike proteins found in the rat. This rat supernatant protein factor-like protein, designated
SPF2, shares 77% and 90% sequence identity with human and rat SPF, respectively,
including a GTP-binding motif as indicated by photoaffinity labeling of SPF2 (Novoselov,
Peshenko et al. 1996; Merkulova, Andreeva et al. 1999), also rat SPF is known to
stimulate squalene monooxygenase in vitro (Shibata, Arita et al. 2001). Unlike SPF, this
protein and its human homolog appear to be expressed predominantly in respiratory
and epithelial tissue (Novoselov, Peshenko et al. 1996; Merkulova, Andreeva et al.
1999; Kempna, Zingg et al. 2003), and a role for this protein has not yet been
described. Our studies demonstrate that SPF2 is approximately 50% as effective as
SPF in stimulating squalene monooxygenase activity, and, like SPF, could be activated
by protein kinase A. While this suggests that SPF2 may also be involved in regulating
cholesterol synthesis, its lesser activity relative to SPF and the greater degree of
inhibition by GTP and GDP raise the possibility that this protein has other roles in the
cell.
Recent studies by Kempna et al. (Kempna, Zingg et al. 2003) demonstrated that all
three human SPF proteins bind tocopherols, phosphatidylinositol, phosphatidylcholine,
and phosphatidylglycerol, and this group postulated that these proteins modulate, in a
tocopherol-sensitive manner, phosphatidylinositol-3-kinase activity. Concurrent studies
done by Panagabko et al. (Panagabko, Morley et al. 2003) on the ligand-specificity of
CRAL-TRIO protein family members including Sec14p, cellular retinal binding protein, αtocopherol transfer protein (α-TTP), and SPF have suggested that the binding of
tocopherols to SPF may not be physiologically relevant. They observed that there is a
considerable amount of ligand promiscuity among the CRAL-TRIO protein family
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members, but that only α-TTP binds α-tocopherol with sufficient avidity to support its
role as a physiological mediator of α-tocopherol's biological activity (Panagabko, Morley
et al. 2003). However, a more recent study suggests that SPF preferentially binds αtocopherylquinone, the principal physiological oxidation product of α-tocopherol (Stocker
and Baumann 2003). It should be noted that the affinity of SPF for squalene is similarly
low, calling into question whether squalene is truly a ligand for SPF; interestingly, SPF
shows greatest affinity for phosphatidylinositol (Panagabko, Morley et al. 2003), and
anionic phospholipids (such as phosphatidylinositol) have long been known to increase
microsomal squalene monooxygenase activity, both in the presence and absence of
SPF (Tai and Bloch 1972). The binding affinities of SPF2 have not been determined, but
Kempna et al. (Kempna, Zingg et al. 2003) showed that human SPF2 could bind αtocopherol and squalene, as well as phosphatidylinositol.
To further complicate SPF biochemistry, the carboxylterminal domain, earlier suggested
to be a GTP-binding domain, has recently been shown to bear significant similarity to a
GOLD (Golgi dynamics) domain (Anantharaman and Aravind 2002; Kempna, Zingg et
al. 2003). This domain is present in a number of proteins involved in Golgi function, and
is predicted to mediate protein–protein interactions involved in assembly of membraneassociated complexes and Golgi function (Anantharaman and Aravind 2002). It has also
been reported that SEC14p-like proteins including human SPFs share homology to
domains found in GTPase activating proteins (GAPs) and guanine nucleotide exchange
factors (GEFs), which suggests a link between the binding of lipids by SEC14p-like
proteins and regulation of Ras and Rho GTPases (Aravind, Neuwald et al. 1999). These
apparently diverse actions of SPF-like proteins, coupled with the demonstration herein
that SPF2 is, like SPF, able to stimulate squalene monooxygenase in vitro, suggest
these proteins may serve multifunctional roles in the cell, perhaps on a tissue-specific
basis.
The presence of a putative GTP-binding motif in the carboxylterminal domain of SPF2
raised the possibility that GTP or other nucleotides might modulate the activity of this
protein. The addition of GTP or GDP blocked the ability of SPF2 to stimulate squalene
epoxidation, but activity could be maintained by the inclusion of α-tocopherol. Similar
studies with human SPF revealed a slight inhibition of activity with GTP, and a weak
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ability of GTP and GDP to reduce SPF activity in rat liver cytosol (Mokashi, Singh et al.
2004). The addition of these nucleotides to incubations with PKA and PKC did not
affect the activation of SPF2 by these kinases. These results indicate that SPF2 activity
may be modulated by guanine nucleotides, and are consistent with studies that reported
that this protein binds GTP and has weak GTP hydrolase activity (Novoselov, Peshenko
et al. 1996; Kempna, Zingg et al. 2003). The ability of α-tocopherol to block this
inhibition is intriguing; α-tocopherol has been shown to promote the movement of SPF
(termed TAP, tocopherol-associated protein) from the cytosol to the nucleus to activate
reporter gene transcription (Yamauchi, Iwamoto et al. 2001), and α-tocopherol binding
to TAP has been shown to stimulate its ability to activate phosphatidylinositol 3-kinase
(Kempna, Zingg et al. 2003).
Protein kinases A and Cδ were found previously to increase the ability of SPF to
stimulate squalene monooxygenase activity; other serine/threonine kinase isoforms
demonstrated a lesser ability to activate SPF (Singh, Mokashi et al. 2003). Addition of
PKA to SPF2 yielded a 1.5-fold increase in the activity of this protein, somewhat less
than the twofold stimulation of SPF obtained with PKA and PKCδ (Singh, Mokashi et al.
2003). PKCδ was also less effective with SPF2.
In summary rat SPF2 mimics the action of human SPF in an in vitro system.
The mechanism by which phosphorylation activates this protein remains to be
determined.

Copyright © Vishwesh Mokashi 2004
32

CHAPTER 4
INVOLVEMENT OF PHOSPHORYLATION, AND INTERACTION WITH GOLGI FOR
THE SPF-MEDIATED INCREASE IN CHOLESTEROL SYNTHESIS IN RAT
HEPATOMA CELLS
Introduction
SPF differs from other CRAL/TRIO proteins (Sec14p, α-tocopherol transfer
protein, cellular retinal binding protein) in that it contains a 157-amino acid carboxylterminal extension that bears significant similarity to the Golgi dynamics domain
found in a number of proteins involved in Golgi function (Anantharaman and Aravind
2002; Kempna, Zingg et al. 2003). SPF proteins appear to associate with Golgi and
endoplasmic reticular membranes (Kempna, Zingg et al. 2003), and, although Golgi
do not contribute to cholesterol synthesis, they are responsible for moving newly
synthesized cholesterol to the cell surface (Simons and Ikonen 2000).

Recent

studies from our laboratory revealed that SPF is activated by protein kinases A
(PKA) and C (PKC), and that the activated protein increases squalene
monooxygenase activity in vitro by 2-fold over that obtained with unphosphorylated
SPF, and 6-fold over that obtained in the absence of SPF (Singh, Mokashi et al.
2003). The present studies were undertaken to determine if this protein kinasemediated activation of SPF could also be observed in cells in culture through a
stimulation of cholesterol synthesis.

The role of the carboxyl-terminal Golgi

dynamics domain in SPF-stimulated cholesterol synthesis was also evaluated by
deletion analysis and by the use of brefeldin A, which disrupts Golgi function.
Results suggest that SPF can modulate cholesterol synthesis in response to cAMP
levels, and that Golgi function is a necessary component of this regulation.

Experimental Methods
Construction and Bacterial Expression of Modified SPF Proteins — The
codon for serine-289 (TCC), a putative PKA phosphorylation site, was altered in the
human SPF cDNA to encode alanine (GCC) by site-directed mutagenesis with the
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QuickChangeTM Kit (Stratagene) and whole-plasmid amplification. Golgi dynamics
domain deletion constructs (SPF283, SPF292, and SPF383) were created by
polymerase chain amplification with appropriate oligonucleotide primers.

All

mutations and deletions were confirmed by DNA sequence determination on the
final plasmid construct. SPF cDNAs were cloned into the pTYB4 expression vector
(New England Biolabs) and expression in Escherichia coli ER2566 and purification
was carried out as described previously (Singh, Mokashi et al. 2003). Centrifugal
ultrafiltration was used to dialyze and concentrate the eluted proteins in 20 mM Tris
buffer, pH 7.4.

Protein concentration was determined with the Coomassie Plus

Assay Reagent Kit (Pierce) and the proteins were stored at -80°C.
Determination of SPF Activity in vitro — The ability of the modified SPF
proteins to stimulate squalene monooxygenase activity in vitro was determined as
described in the previous chapter with Sprague-Dawley rat liver microsomes (~15
mg of protein/ml, 200 µg/reaction) in a final volume of 0.2 ml. Purified SPF, mutant
and the deletion construct proteins were added at 0.8µg/reaction. Incubations of
SPF with PKA and PKCδ were carried out as described (Singh, Mokashi et al.
2003), following the supplier’s instructions (Calbiochem).

14

C-Squalene was

synthesized by SRI International (Menlo Park, CA) and used at 7 mCi/mmol.
Neutral lipids were extracted with 3 ml of petroleum ether, and, after removing the
solvent by centrifugal evaporation, were resuspended in 50 µl of petroleum ether
and spotted onto silica thin-layer plates (Whatman). Lipids were fractionated in 5%
ethyl acetate in hexane and visualized and quantified by electronic autoradiography
(Packard Instant Imager).
Determination of Transfected SPF Activity in Hepatoma Cells — The SPF
cDNAs were cloned into the mammalian expression vector pcDNA3.1 by
polymerase

chain

amplification

and

plasmid

DNA

prepared

from

E.

coli

transformants with the Wizard Midipreps DNA Purification System (Promega).
McARH7777 rat hepatoma cells were plated at a density of 5 × 104 cells per square
centimeter into 6-well cell-culture plates in 2 ml of Dulbecco’s Modified Eagle’s
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Medium with 10% fetal bovine serum and 1% penicillin/streptomycin/glutamine
solution (day 1). After 24 h the purified plasmid DNA was transfected into the cells
at 1 µg/well with the use of LipofectAMINE-Plus transfection reagent (Invitrogen).
Cell viability after transfection (day 4), as assessed by trypan blue exclusion, was
approximately 80%; transfection efficiency was approximately 70-80%, determined
by cotransfection of a β-galactosidase expression plasmid. On days 3 and 4 the
media was replaced and on day 4
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C-acetate (Amersham Biosciences,

60mCi/mmol) was added (1 µCi/well) and the cells were incubated at 37ºC for 3 h.
The media was removed, the cells were washed twice with 1% phosphate-buffered
saline solution, pH 7.4, harvested by scraping, resuspended in Tris-EDTA buffer, pH
7.4, containing 0.1% Triton X100, and lysed by sonication three times for 5 s with a
Sonic Dismembrator (Fisher Scientific) at medium setting. Lipids were extracted
with a mixture of chloroform/methanol (2:1), subjected to centrifugal evaporation,
resuspended in 50 µl of the same and resolved by silica thin-layer chromatography
in petroleum ether/ethyl ether/acetic acid (60:40:1). Radiolabeled cholesterol was
visualized and quantified by electronic autoradiography and authenticated by
comparison to a cholesterol standard visualized by iodine vapor stain.
Analysis of SPF Protein Expression — The integrity of the bacterially
expressed SPF mutant proteins (S289A, SPF283, SPF292, and SPF383) was
assessed by Coomassie blue staining of the purified proteins after fractionation on
15% sodium dodecyl sulfate–polyacrylamide gels.

The expression of these SPF

proteins in hepatoma cells was assessed by immunoblotting. Cells were harvested
48 h after transfection, lysed by sonication as described above, and the lysate
cleared by centrifugation at 12,000 x g for 30 min at 4°. The cleared lysate was
fractionated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis on 15%
gels, electrophoretically transferred to nitrocellulose membranes, and probed with
chicken polyclonal antibody to human SPF. The immunoblot was developed with a
secondary antibody conjugated to alkaline phosphatase. Molecular mass markers
were obtained from Invitrogen. The expression levels of the various SPF proteins
are shown in Figure 4.1.
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Figure 4.1 Immunoblot of SPF proteins expressed in rat hepatoma cells.
McARH7777 cells were transfected with the indicated SPF expression plasmids and
after 48 h cell lysates were prepared and fractionated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred to nitrocellulose, and immunostained
using antibody to SPF.

Lane 1, molecular mass markers; Lane 2, purified

bacterially expressed SPF; Lane 3, lysate from cells transfected with pcDNA3.1
(note that hepatoma cells do not express endogenous SPF); Lane 4, lysate from
cells transfected with WT-SPF; Lane 5, lysate from cells transfected with
SPF(S289A); Lane 6, lysate from cells transfected with SPF383; Lane 7, lysate from
cells transfected with SPF292; Lane 8, lysate from cells transfected with SPF283.
Lane 2 was loaded with ~5 µg of protein, lanes 3-8 were loaded with ~20 µg of
protein.
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Effect of Dibutyryl-cAMP, PKA Inhibitor, and Brefeldin A on SPF Activity —
Dibutyryl-cAMP, myristoylated cell-permeable protein kinase A inhibitor 14-22
amide, and (+)-brefeldin A were purchased from Calbiochem. Dibutyryl-cAMP was
added to hepatoma cell cultures at a final concentration of 0.2 mM and the PKA
inhibitor was added at a final concentration of 1 µM at various times, as indicated,
14

C-acetate. Brefeldin A (100 nM) was added 3 h prior to the

C-acetate.

For the wash-out experiment the media containing the

prior to the addition of
addition of

14

brefeldin A was removed after 3 h and cholesterol synthesis was measured after a
2-h recovery in fresh media.

Results
Ser-289 is Necessary for the Full Activation of SPF by PKA — Earlier studies
from our laboratory revealed that human SPF is activated by PKA and PKCδ,
presumably by phosphorylation on one or more serine or threonine residues (Singh,
Mokashi et al. 2003).

Sequence comparisons between human and rat SPF

sequences, including rat SPF2, which is also activated by PKA (Mokashi, Singh et
al. 2004), revealed a single PKA consensus sequence (Kennelly and Krebs 1991)
common to the two sequences (Figure 4.2).

To determine if this putative

phosphorylation site, Ser-289, was necessary for the activation by PKA, alanine was
substituted by site-directed mutagenesis. The resulting protein was expressed and
purified from E. coli. Addition of the purified mutant protein, SPF(S289A), to rat liver
microsomes stimulated squalene monooxygenase activity by approximately 2-fold
(results not shown) and to the same extent as wild-type SPF, demonstrating that the
mutation did not impair basal activity (Figure 4.3). However, the 2.3-fold activation
of SPF by PKA was reduced by 60% in the S289A mutant, indicating that
phosphorylation of this site contributes to the activation of SPF. Activation of the
protein by PKCδ was not affected by this mutation.
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Figure 4.2 Amino acid sequence comparison between hSPF and rat SPF2 and
the various possible sites of PKA phosphorylation on hSPF and rat SPF2.

Human SPF

S V Q I S R G S S H Q V E Y E I L

Rat SPF2

S V Q I S R G S S H Q V E Y E I L
Serine 289

Ser289

Ser46

hSPF

CRAL/TRIO

GOLD

Ser289

Thr65

Rat SPF2

Ser344

CRAL/TRIO

38

GOLD

Figure 4.3 Serine-289 is necessary for complete activation of SPF in vitro.
Recombinant SPF(S289A) was incubated in the presence of PKA or PKCδ and
ATP, and the ability of the preparations to stimulate microsomal squalene
monooxygenase was determined. Each value represents the mean ± S. E. of three
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Ser-289 is Necessary for the Stimulation of Cholesterol Synthesis by SPF in
Hepatoma Cells — To determine if phosphorylation of SPF at Ser-289 was
necessary for the stimulation of cholesterol synthesis in SPF-transfected hepatoma
cells, the S289A mutant was expressed in rat McARH7777 hepatoma cells and
cholesterol synthesis was monitored by measuring the incorporation of

14

C-acetate.

Immunoblot analysis demonstrated that the S289A protein was expressed at a level
approximately equivalent to that of wild-type SPF in these cells (Figure 4.1);
however, the mutant protein was unable to stimulate cholesterol synthesis, in
contrast to the nearly two-fold increase seen in cells expressing the wild-type SPF
protein (Figure 4.4). Thus, phosphorylation of SPF at Ser-289 appears necessary
for maximal stimulation of squalene monooxygenase activity in vitro and cholesterol
synthesis in cell culture.
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Figure 4.4 Serine-289 is essential for the SPF-mediated increase in cholesterol
synthesis in rat hepatoma cells.
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Dibutyryl-cAMP Stimulates Cholesterol Synthesis in Cells Expressing SPF —
To determine if SPF activity in cultured cells was modulated by PKA, dibutyrylcAMP, a cell-permeable activator of PKA, was added to hepatoma cell cultures
transfected with the control vector (pcDNA3.1) or wild-type SPF. Dibutyryl-cAMP
produced a 25% increase in cholesterol labeling when added along with
acetate, and a 52% increase when added 2 h prior to the addition

14

14

C-

C-acetate

(Figure 4.5). Dibutyryl-cAMP had no effect on cholesterol synthesis in cells that did
not express SPF (note that hepatoma cells do not express an endogenous SPF –
see Figure 4.1, lane 3).

These results indicate that SPF can be activated in

response to cellular cAMP levels, and that in cells under these culture conditions (in
the absence of dibutyryl-cAMP) SPF is not fully activated.
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Figure 4.5 Cholesterol synthesis is stimulated by dibutyryl-cAMP in cells
expressing SPF.

The ability of 0.2 mM dibutyryl-cAMP to stimulate cholesterol

synthesis in rat hepatoma cells was determined at 0 and 2 h after addition of the
cAMP analogue to the media, as described in “Experimental Procedures”. Each
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value represents the mean ± S. E. of two experiments carried out in duplicate.

Inhibition of PKA Prevents the SPF-mediated Increase in Cholesterol
Synthesis — The above results indicate that SPF must be phosphorylated on Ser289 to stimulate cholesterol synthesis. To confirm a role for PKA in this activation,
a cell-permeable PKA inhibitor peptide was added to SPF-transfected cultures and
cholesterol synthesis was monitored.

The SPF-mediated increase in cholesterol

synthesis was completely reversed by one hour after addition of the inhibitor, and
the loss of SPF activity was maintained through 24 h (Figure 4.6).

The PKA

inhibitor had no effect on cholesterol synthesis in cells that did not express SPF.
These results suggest that phosphorylation of SPF by PKA is a dynamic process
and that, in the absence of PKA activity, SPF is rapidly inactivated.
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Figure 4.6 The stimulation of cholesterol synthesis by SPF is prevented by a
PKA inhibitor.

The PKA inhibitor 14-22 amide (PKAi, 1 µM) was added to

hepatoma cells expressing SPF or containing the control vector (pcDNA3.1) and
cholesterol labeling was measured at 0, 1, 6, 12, and 24 h. The -1 h time-point
indicates cholesterol synthesis in the absence of the PKA inhibitor.

Each value

Cholesterol Synthesis
(% of Control)

represents the mean ± S. E. of two experiments carried out in duplicate.
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Deletion of the Golgi Dynamics Domain Activates SPF in vitro but Prevents
the Activation of SPF in Cell Culture — The carboxyl-terminal domain of SPF
(amino acids 290 to 403) shows sequence similarity to proteins involved in Golgi
function, including the p24 family, which are involved in coated vesicle transport
from the endoplasmic reticulum to Golgi (Anantharaman and Aravind 2002). This
domain is not found in other lipid transfer proteins in the CRAL/TRIO family,
including Sec14p and α-tocopherol transfer protein. To determine if this domain
was necessary for the SPF-mediated stimulation of squalene monooxygenase in
vitro, SPF was truncated at amino acid 283 and the shortened protein expressed
and purified from E. coli (Figure 4.1). Although the shortened protein lacked Ser289, the required PKA phosphorylation site, its activity was 40% greater than that of
full-length SPF that had been activated by incubation with PKA (Figure 4.7). The
truncated protein could not be further activated by PKA or PKCδ. In contrast to this
activation in vitro, deletion of the Golgi dynamics domain greatly reduced the ability
of SPF to stimulate cholesterol synthesis in hepatoma cells (Figure 4.8). SPF283
was only 38% as effective as full-length SPF, and surprisingly, SPF292, which
retains the PKA phosphorylation site (Ser-289) was completely inactive. SPF383,
from which only 20 amino acids were removed, retained the full ability to stimulate
cholesterol synthesis although the amount of this protein expressed in these cells
was much higher than WT SPF.

These results suggest that an interaction with

Golgi or Golgi proteins is necessary for the stimulation of cholesterol synthesis in
cells, but that, paradoxically, this domain hinders the stimulation of squalene
monooxygenase in vitro.

The 3-dimensional view of the truncated proteins is

shown in Figure 4.9.
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Figure 4.7 Deletion of the Golgi dynamics domain increases the stimulation of
microsomal squalene monooxygenase by SPF.

The stimulation of squalene

monooxygenase activity in rat liver microsomes by SPF and SPF283, and their
ability to be activated by PKA and PKC, was determined as described in
“Experimental Procedures”. Each value represents the mean ± S. E. of two or more
experiments carried out in duplicate.
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Figure 4.8 Deletion of the Golgi dynamics domain reduces the stimulation of
cholesterol synthesis by SPF in cell culture. The ability of SPF383, SPF292,
and SPF283 to stimulate cholesterol synthesis in hepatoma cells was determined as
described in “Experimental Procedures”. Each value represents the ± S. E. of two
or more experiments carried out in duplicate.
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Figure 4.9 Various deletion constructs of hSPF.
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Golgi are Required for the Stimulation of Cholesterol Synthesis by SPF — To
determine if an interaction of SPF with Golgi was required for the stimulation of
cholesterol synthesis in hepatoma cells, brefeldin A, which dissociates Golgi and
disrupts Golgi function, was added to the cells 3-h prior to the addition of

14

C-

acetate. Brefeldin A completely prevented the stimulation of cholesterol synthesis
by SPF (Figure 4.10). The inhibition by brefeldin A could be reversed by replacing
the media and allowing the cultures to recover for 2 h. Brefeldin A had no effect on
cholesterol synthesis in cells that did not express SPF.
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Figure 4.10 Brefeldin A prevents the stimulation of cholesterol synthesis by
SPF in cell culture. Brefeldin A (BFA) was added to hepatoma cells 3 h prior to the
addition of

14

C-acetate and cholesterol labeling was determined. For the washout

experiment the media was replaced and 2 h later acetate incorporation into
cholesterol was determined. Each value represents the ± S. E. of two experiments
performed in duplicate.
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Discussion
The ability of supernatant protein factor to stimulate cholesterol synthesis
when expressed in hepatoma cells, first noted by Shibata et al. (Shibata, Arita et al.
2001), has added a surprising new dimension to this long-known but poorly
understood protein. In the present studies we show that this stimulation is wholly
dependent on phosphorylation by PKA at Ser-289, and that an apparent interaction
with Golgi is further required. The mechanism of this Golgi effect is unknown, but is
evidenced by the loss of SPF activity in cells treated with brefeldin A, a
disaggregator of Golgi, and the loss of SPF activity upon deletion of the carboxylterminal Golgi dynamics domain thought to be involved in the interaction of Golgiassociated proteins.

Paradoxically, the deletion of this domain significantly

enhances the ability of SPF to stimulate squalene epoxidation in microsomal
preparations, the original activity ascribed to SPF.

This finding appears to

dissociate the cholesterolgenic effect of SPF in whole cells from the stimulation of
this cholesterolgenic enzyme in vitro, and with both effects the mechanism of the
stimulation by SPF remains unknown.
In the present studies cholesterol synthesis was estimated by radiolabel
incorporation from

14

C-acetate added to the media. Although this is a widely used

and generally reliable method for determining relative rates of cholesterol synthesis
(Dietschy and Spady 1984), the “pool size” of unlabeled acetate in the cell will affect
radiolabel incorporation, and it is formally possible that SPF might increase label
incorporation by decreasing the amount of unlabeled acetate available for
incorporation, or by enhancing the uptake or activation of radiolabeled acetate in the
cell. We measured the accumulation of

14

C after 1 h of incubation with

14

C-acetate

and found no effect of SPF expression on the total radioactivity in cells, indicating
that SPF does not affect the uptake of acetate (results not presented). Our studies
with a PKA activator (dibutyryl-cAMP) and inhibitor (14-22 amide), as well as with
brefeldin A similarly argue against an effect of SPF on the unlabeled acetate pool;
the effects of these compounds on cholesterol synthesis were seen almost
immediately, within the 3-h time-period of the assay, and in particular the brefeldin A
washout experiment rapidly restored SPF activity (Fig. 9). It is difficult to envision
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how this effect on Golgi might mediate a change in acetate levels in the cell through
SPF; rather, they are consistent with the hypothesis that SPF acts to rapidly and
directly modulate cholesterol synthesis in response to cellular and extracellular
signals, including cAMP (Singh, Mokashi et al. 2003).
The ability of SPF to increase cholesterol synthesis in whole cells, coupled
with its ability to stimulate squalene monooxygenase activity in microsomes, implies
that SPF increases cholesterol synthesis by stimulating squalene monooxygenase
activity in cells. However, squalene monooxygenase is not generally regarded as
the rate-limiting step in cholesterol synthesis, a distinction reserved for HMG-CoA
reductase.

Thus, increasing squalene monooxygenase activity would not be

expected to increase cholesterol synthesis, raising the possibility that SPF promotes
cholesterolgenesis by additional mechanisms. Our finding that removal of the Golgi
dynamics domain from SPF impairs its ability to increase cholesterol synthesis in
cell culture while significantly increasing its ability to stimulate squalene
monooxygenase activity in microsomes is consistent with this suggestion.

This

paradoxical result argues that the increase in cholesterol synthesis is not mediated
through an increase in squalene monooxygenase activity, but rather involves an
interaction of SPF with Golgi or Golgi-associated proteins. It should be noted that
Shibata et al. (Shibata, Arita et al. 2001) reported that SPF expression in hepatoma
cells led to an increase in squalene levels (as well as lanosterol and cholesterol), an
effect that also would not be expected if SPF acted only on squalene
monooxygenase.
The dependency of SPF on intact Golgi and phosphorylation bears strong
similarity to the regulation of oxysterol binding proteins. This family of proteins has
been shown to associate with Golgi in response to cholesterol depletion and to be
phosphorylated by an unidentified Golgi-associated protein kinase (Ridgway,
Badiani et al. 1998; Storey, Byers et al. 1998). Treatment of cells with brefeldin A
leads to dephosphorylation (Ridgway, Badiani et al. 1998), as does severe
cholesterol depletion (Mohammadi, Perry et al. 2001). Notably, overexpression of
oxysterol binding protein in mouse hepatoma cells increased the expression of
several cholesterolgenic enzymes, including HMG-CoA reductase, and increased
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cholesterol synthesis by 80% (Lagace, Byers et al. 1997).

The present studies

suggest a new and parallel kinase-dependent regulatory pathway for the rapid
modulation of cholesterol synthesis in which cAMP and PKA activate SPF to directly
stimulate cholesterol synthesis.

Copyright © Vishwesh Mokashi 2004
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CHAPTER 5
SUPERNATANT PROTEIN FACTOR STIMULATES HMG-COA REDUCTASE IN
CELL CULTURE AND IN VITRO
Introduction
Cholesterol synthesis is a highly regulated pathway subject to transcriptional,
translational, and post-translational control. Although all cholesterolgenic enzymes
appear to be subject to some level of coordinate regulation (Sakakura, Shimano et
al. 2001).

HMG-CoA reductase is thought to be the rate-controlling step in the

overall pathway and thus is subject to both long-term and short-term regulatory
mechanisms (Russell 1992; Ness and Chambers 2000).

Short-term regulatory

mechanisms include inactivation by phosphorylation (Ingebritsen 1983), changes in
the rate of degradation in response to hormones, tocotrienols, sterols, and sterol
intermediates (Parker, Pearce et al. 1993; Ness and Chambers 2000; Sever, Song
et al. 2003) and membrane fluidity-mediated effects on activity (Davis and
Poznansky 1987). The mechanisms by which membrane fluidity is modulated in
cells, and how this alters HMG-CoA reductase activity, remain to be defined.
Shibata et al. (Shibata, Arita et al. 2001) recently reported that SPF, when
transfected into hepatoma cells that do not express endogenous SPF, increases
cholesterol synthesis by nearly three-fold. Our studies confirm this observation
(Chapter 4).

Because squalene monooxygenase is not considered to be rate-

limiting in cholesterol synthesis, these findings suggest that SPF may affect
additional cholesterolgenic enzymes, perhaps in a general fashion by altering the
lipid composition of the associated endoplasmic reticulum.

The present studies

were undertaken to determine where SPF acts in the cholesterolgenic pathway to
enhance cholesterol synthesis. The various inhibitors used in this study are shown
in Fig 5.1. The results reveal that SPF stimulates both squalene monooxygenase
and HMG-CoA reductase in vitro as well as in cell culture.
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Figure 5.1 Various inhibitors used in this study
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Experimental Methods
Hepatoma Cell Culture and Transfection — The human SPF cDNA was cloned
into the mammalian expression vector pcDNA3.1 by polymerase chain amplification
and plasmid DNA was prepared from E. coli transformants with the Wizard
Midipreps DNA Purification System (Promega).

McARH7777 rat hepatoma cells

were plated at a density of 5 × 104 cells per square centimeter into 6-well cellculture plates in 2 ml of Dulbecco’s Modified Eagle’s Medium with 10% fetal bovine
serum and 1% penicillin/streptomycin/glutamine solution (day 1).

After 24 h the

purified plasmid DNA was transfected into the cells at 1 µg/well with the use of
LipofectAMINE-Plus

transfection

reagent

(Invitrogen).

Cell

viability

after

transfection, as assessed by trypan blue exclusion on day 4, was approximately
80%;

transfection

efficiency

was

approximately

70-80%,

determined

by

cotransfection of a β-galactosidase expression plasmid.
Determination of Cholesterol Synthesis in Hepatoma Cells — Cholesterol
synthesis was determined on day 4 in vector-transfected cells (pcDNA3.1) and cells
containing the SPF expression construct.
mCi/mmol) or

14

14

C-Acetate (Amersham Biosciences, 60

C-mevalonate (Amersham Biosciences, 60mCi/mmol) was added (1

µCi/well) and the cells were incubated at 37 °C for 3 h. Mevinolin (1 µM, Sigma
Chemical Co.) was included in incubations with

14

C-mevalonate to block HMG-CoA

reductase, and lipid-replete serum was used in all studies.

The media was

removed, the cells were washed twice with 2 ml of 1% phosphate-buffered saline
solution, pH 7.4, harvested by scraping, resuspended in 20 mM Tris-EDTA buffer,
pH 7.4, containing 0.1% Triton X-100, and lysed by sonication three times for 5 s
with a Sonic Dismembrator (Fisher Scientific) at medium setting.

Lipids were

extracted without saponification (to allow quantitation of cholesterol-esters) with a
mixture of chloroform/methanol (2:1), subjected to centrifugal evaporation,
resuspended in 50 µl of the same and resolved by silica thin-layer chromatography
(Whatman, Inc.) in petroleum ether/ethyl ether/acetic acid (60:40:1). Radiolabeled
cholesterol and cholesterol-esters were visualized and quantified by electronic
autoradiography (Packard Instant Imager) and authenticated by comparison to
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standards visualized by iodine-vapor stain, and cholesterol was also authenticated
by gas-chromatographic/mass spectrometry of the eluted sample.

Cholesterol

synthesis was normalized to that of cells transfected with the vector (pcDNA3.1),
setting synthesis in these cells at 100%.
For the pulse-chase experiment, cells were incubated with

14

C-acetate for 3

hr, after which the media was decanted, the cells were washed, and fresh media
added. Radiolabeled cholesterol and cholesterol-esters were quantified in the cells
and media at various times thereafter; the media was clarified by low-speed
centrifugation to remove cells and cell debris, and cholesterol was quantified in both
the supernatant and cell pellet as described above.
Determination of Squalene Synthesis in Hepatoma Cells — Squalene
synthesis from

14

C-acetate or

14

C-mevalonate was measured in vector-transfected

cells (pcDNA3.1) and cells containing the SPF expression construct, utilizing 60 µM
terbinafine (TCI America, Inc.) to block squalene monooxygenase, the subsequent
enzyme in the pathway. Mevinolin (1 µM) was included in incubations with

14

C-

mevalonate. Radiolabeled substrate was added at 1 µCi/well and the cells were
incubated at 37 °C for 3 h. The media was removed, the cells washed twice with
1% phosphate-buffered saline solution, pH 7.4, harvested by scraping, resuspended
in 20 mM Tris-EDTA buffer, pH 7.4, and lysed by sonication three times for 5 s.
Lipids were saponified in 0.5 ml of methanolic potassium hydroxide at 80 °C for 1 h.
Neutral lipids were extracted with 5 ml of petroleum ether, subjected to centrifugal
evaporation, resuspended in 50 µl of the same and resolved by silica thin-layer
chromatography in 5% ethyl acetate in hexane.

Radiolabeled squalene was

quantified by electronic autoradiography and authenticated by comparison to a
squalene standard visualized by iodine-vapor stain.
Determination of 2,3-Oxidosqualene Synthesis in Hepatoma Cells — 2,3Oxidosqualene synthesis from

14

C-acetate or

14

C-mevalonate was measured in

vector-transfected cells (pcDNA3.1) and cells containing the SPF expression
construct in the presence of 1.5 mM AMO 1618 (Calbiochem), an inhibitor of
oxidosqualene cyclase, the subsequent enzyme in the pathway. Mevinolin (1 µM)
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was included in incubations with

14

C-mevalonate.

Radiolabeled substrate was

added at 1 µCi/well and cells were incubated at 37 °C for 3 h, after which the media
was removed, the cells were washed twice with 1% phosphate-buffered saline
solution, pH 7.4, harvested by scraping, resuspended in 20 mM Tris-EDTA buffer,
pH 7.4, containing 0.1 % Triton X-100 and lysed by sonication three times for 5 s.
Lipids were saponified in 0.5 ml of methanolic potassium hydroxide at 80 °C for 1 h.
The neutral lipids were extracted with 5 ml of petroleum ether, subjected to
centrifugal evaporation, resuspended in 50 µl of the same and resolved by silica
thin-layer chromatography in 5% ethyl acetate in hexane.

Radiolabeled 2,3-

oxidosqualene was quantified by electronic autoradiography.
Determination of HMG-CoA Reductase Activity in vitro — The microsomal
fraction (100,000 x g pellet, resuspended at ~15 mg of protein/ml in 20 mM Tris
buffer, pH 7.4) and the cytosolic fraction (100,000 X g supernatant, diluted to ~15
mg of protein/ml) were prepared by standard procedures from the livers of untreated
male Harlan Sprague-Dawley rats (~200 g).

HMG-CoA reductase activity was

determined as described by Brown and Goldstein (Brown, Dana et al. 1974), as
follows:

Microsomal protein (100 µg) was incubated at 37 °C for 3 h in a final

volume of 200 µl of 0.1 M potassium phosphate buffer, pH 7.5, containing 20 mM
glucose

6-phosphate,

2.5

mM

NADP+,

1

unit

of

glucose

dehydrogenase (Sigma), 5 mM dithiothreitol, and 0.2 µCi

14

6-phosphate

C-HMG-CoA (55

mCi/mmol, American Radiolabeled Chemicals, Inc.). Purified recombinant human
SPF or rat liver cytosol were added as indicated. The reaction was stopped by
addition of 20 µl of 6 M HCl, incubated at 37 °C for 30 min to convert the product to
14

C-mevalonolactone, and extracted twice with 5 ml of diethyl ether/ethyl acetate.

The ether extracts were evaporated to dryness by centrifugal evaporation and the
lipids separated by thin layer chromatography in benzene/acetone (1:1, v/v).
14

C-Mevalonolactone was authenticated by comparison to a mevalonolactone

standard

visualized

by

iodine-vapor

stain

and

quantified

by

electronic

autoradiography. Microsomal squalene monooxygenase activity was determined as
described previously (Singh, Mokashi et al. 2003).
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Activation of SPF by Protein Kinase A and Cδ — Protein kinase A and Cδ
incubations with SPF were carried out according to the manufacturer’s instructions
with mouse recombinant PKA catalytic unit Cα, 5 units (Calbiochem) or 0.25 units of
human recombinant PKC isozyme δ (Calbiochem), 5 µg of SPF, and 3 mM ATP for
30 min at 30 °C.

Unbound nucleotide was removed by centrifugal filtration

(Microcon concentrator, 30 kD cutoff) and SPF protein was resuspended in 20 mM
Tris buffer, pH 7.4, and added to microsomal assays as described above.
Immunoblot Analysis of HMG-CoA Reductase and Squalene Monooxygenase
Expression —

Hepatoma cells were harvested 48 h after transfection, lysed by

sonication as described above, and the lysate cleared by centrifugation at 12,000 x
g for 30 min at 4 °C.

The cleared lysate was fractionated by sodium dodecyl

sulfate–polyacrylamide gel electrophoresis on 8.5% gels, electrophoretically
transferred to nitrocellulose membranes, and probed with polyclonal antibody to
human HMG-CoA reductase (Upstate USA, Inc.) or human squalene monooxygenase
(prepared by Animal Pharm Services, Inc). The immunoblots were developed with a
secondary antibody conjugated to alkaline phosphatase.
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Results
SPF increases cholesterol synthesis — Shibata et al. (Shibata, Arita et al.
2001)reported that expression of SPF in hepatoma cells increases cholesterol
synthesis by 2-3-fold, but did not define the mechanism or parameters of this
stimulation.

To confirm and explore this unexpected finding, we measured

cholesterol synthesis from

14

C-acetate in McARH7777 rat hepatoma cells at various

times after transfection of an SPF-expression plasmid. As shown in Fig. 5.2A, SPF
expression increased cholesterol synthesis by approximately 75% and maintained
elevated rates for at least 24 hr (note that in these experiments time 0 represents 48
h after transfection).

Cholesterol synthesis returned to normal levels by 48 h

despite the continued expression of SPF (data not shown), indicating that the cells
countered the SPF-mediated increase in cholesterol by down-regulating synthesis
at one or more points in the pathway. To determine how the newly synthesized
cholesterol was processed in the cell, a pulse-chase experiment was carried out in
which cells were incubated with

14

C-acetate for 3 h, starting at time 0, after which

the media was replaced and radiolabeled cholesterol and cholesterol-esters were
quantified at various times thereafter in the cells and media. As shown in Fig. 5.2B,
cholesterol labeling in SPF-transfected cells was doubled at 3 h, relative to vectortransfected cells (Fig. 5.2C), and returned to control levels by 24 h. Cholesterolesters in SPF-transfected cells increased slightly at 6 h and then declined in
conjunction with cholesterol labeling, whereas esters increased slightly over time in
vector-transfected cells.

Cholesterol in the clarified media from SPF-transfected

cells increased over the period of the experiment, such that the “excess” cholesterol
synthesized in the first 3-h could be accounted for in the media by 24 h. Cholesterol
in the media of vector-transfected cells increased only slightly over the period of the
experiment.

These results indicate that SPF stimulates cholesterol synthesis in

hepatoma cells for up to 72 h after transfection and that this newly synthesized
cholesterol is largely secreted from the cells into the media.
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Fig. 5.2 SPF expression increases cholesterol synthesis and cholesterol
secretion into the media. A,

14

C-Acetate was added to SPF-transfected or vector-

transfected cells at the times indicated and radiolabeled cholesterol was quantified
after 3 h. Each value represents the mean ± S. E. of two experiments carried out in
duplicate. B, SPF-transfected cells or C, vector-transfected cells were incubated
with

14

C-acetate for 3 h, after which the media was replaced and radiolabeled

cholesterol and cholesterol-esters were quantified at the times indicated. The open
symbols indicate labeled cholesterol in the clarified media. Each value represents
the average and standard deviation of duplicate determinations.
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SPF increases mevalonate synthesis — Preliminary studies revealed that SPF
expression increased cholesterol synthesis by nearly two-fold when measured by
14

C-acetate incorporation, but that this effect was blunted when

substituted for

14

14

C-mevalonate was

C-acetate. These results suggested that SPF was acting at or prior

to the synthesis of mevalonate. To test this hypothesis, squalene synthesis was
measured in these cells in the presence of terbinafine, a squalene monooxygenase
inhibitor, to prevent squalene from being further metabolized. Squalene synthesis
from

14

C-acetate was increased by 50% in cells transfected with the SPF expression

vector when compared to vector-transfected control cells, but was unchanged from
control values when measured with

14

C-mevalonate (Fig. 5.3).

These results

support the contention that SPF stimulates mevalonate synthesis.

Because

mevinolin, a potent inhibitor of HMG-CoA reductase, was included in the assays
utilizing

14

C-mevalonate, these results further indicate that SPF does not affect

enzymes after HMG-CoA reductase and prior to squalene monooxygenase,
including squalene synthase.
SPF increases squalene monooxygenase activity in hepatoma cells — As
shown in Fig. 5.4, cholesterol synthesis was increased in SPF-expressing cells by
78% when measured with

14

C-acetate; however, cholesterol synthesis was

increased by 42% when measured with

14

C-mevalonate in the presence of

mevinolin, indicating that SPF was also acting downstream of HMG-CoA reductase.
Because SPF is well established to stimulate squalene monooxygenase in vitro, we
measured

the

synthesis

2,3-oxidosqualene

(the

product

of

squalene

monooxygenase) in the presence of AMO 1618, an inhibitor of oxidosqualene
cyclase, to prevent 2,3-oxidosqualene from being converted to lanosterol.
Oxidosqualene synthesis was increased by 50% when measured with
and by 32% when measured with

14

14

C-acetate

C-mevalonate in the presence of mevinolin

(Fig.5.3), indicating that SPF expression increases squalene monooxygenase
activity in hepatoma cells.

Immunoblot analysis with antibody to squalene

monooxygenase demonstrated that squalene monooxygenase expression was not
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increased in cells that express SPF, indicating that the effect of SPF is on enzyme
activity (see Fig 5.4)
SPF also stimulates oxidosqualene cyclase in vitro (Srikantaiah, Hansbury et
al. 1976; Caras and Bloch 1979), but it was not possible to test the effect of SPF
expression on this enzyme in cell culture, as hepatoma cells do not efficiently take
up post-squalene intermediates (unpublished data). SPF was reported to not affect
cholesterolgenic enzymes downstream of lanosterol (Caras and Bloch 1979).
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Fig. 5.3 Effect of SPF expression on squalene, 2,3-oxidosqualene, and
cholesterol synthesis from

14

14

C-acetate and

C-mevalonate in hepatoma cells.

Product formation is reported as a percentage of the amount formed in cells
transfected

with

the

pcDNA3.1

vector,

and

determined

as

described

in

“Experimental Procedures”. Each value represents the mean ± S.E. of two to four
experiments carried out in duplicate.
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Fig. 5.4 SPF expression does not alter HMG-CoA reductase or squalene
monooxygenase expression. Cleared lysates prepared from vector-transfected or
SPF-transfected cells were fractionated by SDS-polyacrylamide gel electrophoresis
and transferred to nitrocellulose for immunodetection with polyclonal antibodies to
HMG-CoA reductase (HMGR) or squalene monooxygenase (SM).
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SPF stimulates HMG-CoA reductase in vitro — The increase in mevalonate
synthesis in cells expressing SPF suggests that SPF increases either the
expression or activity of one or more enzymes upstream of mevalonate.
Immunoblot analysis with antibody to HMG-CoA reductase demonstrated that the
expression of this enzyme was not increased in cells that express SPF (Fig. 5.4).
The expression of HMG-CoA synthase and β-ketothiolase, the enzymes that
precede HMG-CoA reductase in the pathway, was not examined.

However,

because HMG-CoA reductase is believed to be the rate-limiting enzyme in
cholesterol synthesis, these results suggest that SPF directly stimulates the activity
of this enzyme. To test this hypothesis, microsomes were prepared from rat liver
and the effect of purified recombinant SPF on mevalonate synthesis from

14

C-HMG-

CoA was determined. As shown in Fig. 5.5, addition of SPF increased HMG-CoA
reductase activity by up to 60%, with maximum stimulation occurring at 0.8 µg of
SPF per assay. The SPF-activation curve for HMG-CoA reductase paralleled that
for squalene monooxygenase, with greater amounts of SPF proving inhibitory, as
has been seen previously with squalene monooxygenase (Singh, Mokashi et al.
2003; Mokashi, Singh et al. 2004).

Rat liver cytosol also stimulated HMG-CoA

reductase activity to a similar extent, but the stimulatory range was narrow, and
higher concentrations were strongly inhibitory.

The reason for the inhibition at

higher concentrations of SPF and cytosol has not been determined.
Our recent studies have revealed that SPF is activated by protein kinases A
and C in vitro, indicating that phosphorylation may play a role in the regulation of
SPF activity (Singh, Mokashi et al. 2003). To determine if activation of SPF could
be seen with HMG-CoA reductase, SPF was incubated with PKA or PKCδ and ATP
prior to addition to microsomes. As shown in Fig. 5.6, the stimulation of HMG-CoA
reductase afforded by SPF was nearly doubled by incubation with PKA, with a
lesser increase with PKCδ.

These results closely resemble those seen with

squalene monooxygenase previously (Singh, Mokashi et al. 2003) and argue that
SPF stimulates HMG-CoA reductase and squalene monooxygenase by identical
mechanisms.
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Fig. 5.5 SPF and cytosol stimulate HMG-CoA reductase in vitro.

HMG-CoA

reductase (HMGR) and squalene monooxygenase (SM) activity were determined as
described in “Experimental Procedures” in the presence of different amounts of SPF
or rat liver cytosol, as indicated. Each value represents the mean ± S.E. of three
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Fig. 5.6 Activation of SPF by PKA and PKCδ increases its ability to stimulate
HMG-CoA reductase in vitro. SPF or SPF activated by incubation with PKA or
PKCδ and ATP was added to rat liver microsomal preparations and HMG-CoA
reductase activity was determined as described in “Experimental Procedures”.
Each value represents the mean ± S.E. of two or three experiments carried out in

350

HMGR
SM

300
250
200
150
100
50
δ
+
SP
F

+
F
SP
70

PK
C

PK
A

F
SP

m

es

0
M
ic
ro
so

Enzyme Activity
(% of Microsomal Control)

duplicate.

Discussion
SPF has long been known to stimulate squalene monooxygenase and
oxidosqualene cyclase in microsomal preparations (Tai and Bloch 1972; Saat and
Bloch 1976; Caras and Bloch 1979).

In the present studies SPF is shown to

stimulate squalene monooxygenase in cultured hepatoma cells, indicating that the
effect is not restricted to microsomal preparations; moreover, SPF also increased
HMG-CoA reductase activity, possibly in cell culture and when added to rat liver
microsomes.

These results suggest that SPF is able to modulate cholesterol

synthesis at two key regulatory points in the cholesterolgenic pathway, presumably
by the same mechanism.

Cholesterol synthesis was elevated by 48 h after

transfection and continued for another 24 h, after which synthesis returned to
control levels despite the continued presence of SPF. This result suggests that the
cells compensate for the presence of SPF by downregulating cholesterol synthesis
at other points in the pathway, or by inactivating SPF by dephosphorylation.
Current studies are directed at identifying this compensatory mechanism.

The

newly synthesized cholesterol is rapidly processed in the cell and is fully secreted
into the media as free cholesterol by 24 h. The stimulation afforded by SPF cannot
be generalized to all cholesterolgenic enzymes, as the conversion of mevalonate to
squalene is unaffected by SPF; this also excludes a general effect on membranebound enzymes, as squalene synthase is unaffected by SPF.

Although

oxidosqualene cyclase (lanosterol synthase) is also stimulated by SPF when
assayed in microsomal preparations (Saat and Bloch 1976; Caras and Bloch 1979),
we were not able to determine if SPF stimulates enzymes downstream of squalene
monooxygenase, including oxidosqualene cyclase, in cultured cells, as hepatocytes
do not readily take up post-squalene and sterol intermediates. Caras and Bloch
(Caras and Bloch 1979) reported that SPF did not affect the subsequent conversion
of lanosterol to cholesterol.
Although HMG-CoA reductase enzyme levels are modulated by sterols and
non-sterol

cholesterol

intermediates

at

both

the

transcriptional

and

post-

transcriptional level (Ness and Chambers 2000), SPF did not affect HMG-CoA
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reductase or squalene monooxygenase expression, and the stimulatory effect in
cells could be fully replicated by adding SPF to microsomal preparations.

This

stimulation could also be observed with rat liver cytosol, although, in contrast to
squalene monooxygenase (Singh, Mokashi et al. 2003), the stimulation of HMGCoA reductase by cytosol was evidenced over a narrow range, with higher
concentrations proving to be strongly inhibitory.

Although Lehrer et al. (Lehrer,

Panini et al. 1981) noted that cytosol stimulated HMG-CoA reductase (see
discussion below), the modest stimulation produced by cytosol (less than two-fold)
and the narrow effective range may explain why this effect was not explored in
earlier studies.

Notably, the stimulation of HMG-CoA reductase and squalene

monooxygenase by SPF can be increased several-fold by phosphorylation, with
PKA being most effective. This suggests that SPF may serve as a short-term, rapid
modulator of cholesterol synthesis in cells in response to diverse hormonal and
environmental signals.
Although SPF has been proposed as a carrier protein for squalene and has
been shown to facilitate the movement of squalene between membranes in vitro
(Friedlander, Caras et al. 1980; Kojima, Friedlander et al. 1981; Fuks-Holmberg and
Bloch 1983; Shibata, Arita et al. 2001), squalene transfer would not appear to be
relevant to the stimulation of HMG-CoA reductase, raising the possibility that SPF
acts by some other mechanism.

SPF has a four-fold higher affinity for

phosphatidylinositol than for squalene (Panagabko, Morley et al. 2003), suggesting
that SPF may be a phosphatidylinositol transfer protein, analogous to Sec14p in
yeast. Indeed, SPF and Sec14p are both members of the CRAL/TRIO family of
lipid-binding proteins, and share approximately 30% sequence identity. SPF binds
tightly to anionic, but not cationic, phospholipid vesicles (Caras, Friedlander et al.
1980), and anionic phospholipids (phosphatidylinositol and phosphatidylserine)
increase squalene monooxygenase activity by 8-fold alone but 40-fold when SPF is
included (Tai and Bloch 1972). These findings are consistent with a role for SPF in
anionic phospholipid transfer; however, anionic phospholipids have not been shown
to stimulate HMG-CoA reductase (Berde, Heller et al. 1977).

And, although

numerous early reports suggested that membrane fluidity, as mediated by
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cholesterol content, modulates HMG-CoA reductase activity, many of these early
findings can now be reinterpreted in light of our current understanding of how
sterols promote Insig-mediated ubiquitination and degradation of HMG-CoA
reductase (Sever, Song et al. 2003; Sever, Yang et al. 2003). Nonetheless, Lehrer
et al. (Lehrer, Panini et al. 1981), in studies on the inhibition of HMG-CoA reductase
by lipids, reported that rat liver cytosol reversed oleic acid and oleoyl-CoA inhibition
and stimulated HMG-CoA reductase activity in microsomes by up to 33%. Although
this stimulation was attributed to the presence of phosphatase in the cytosol which
could reactivate phosphorylation-inactivated enzyme (Hardie 1992; Omkumar,
Darnay et al. 1994), the possibility was considered that this stimulation was
mediated by a cytosolic lipid-binding protein.

The present findings that SPF

stimulates HMG-CoA reductase in microsomes are remarkably consistent with this
early observation, and suggest a new means by which cholesterol synthesis is
regulated in the cell.

Copyright © Vishwesh Mokashi 2004
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CHAPTER 6
CONCLUSIONS
Regulation of HMG-CoA Reductase
The endoplasmic reticulum bound-enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase, is generally considered as catalyzing the rate limiting step in
cholesterol biosynthesis (Bucher, Overath et al. 1960).
HMG-CoA reductase is regulated by several mechanisms. Feedback regulation
of hepatic cholesterol synthesis was recognized nearly 50 years ago (Gould 1950;
Gould 1951; Gould 1953).

The activity of HMG-CoA reductase can be altered in

response to changes in dietary cholesterol (Brown, Dana et al. 1974). In addition to
dietary factors, HMG-CoA reductase activity can be modified at different levels; these
include the transcription, translation, protein turnover and regulation of catalytic activity
by phosphorylation/dephosphorylation. The possibility that HMG-CoA reductase could
be regulated by phosphorylation/dephosphorylation was introduced by Beg et al. (Beg,
Allmann et al. 1973). Subsequent studies revealed that HMG-CoA reductase could be
phosphorylated and inactivated by an AMP-activated protein kinase (Parker, Miller et al.
1989; Clarke and Hardie 1990; Hardie 1992). The site of phosphorylation was identified
as serine 871 (Clarke and Hardie 1990).

Recent studies have revealed that one

important form of feedback regulation of HMG-CoA reductase involves the control of the
rate of protein degradation (Yang, Espenshade et al. 2002).
A study done by Asslan et al. in 1998 demonstrated that HMG-CoA reductase
activity could be modified by herbimycin, a non-specific tyrosine kinase inhibitor (Asslan,
Pradines et al. 1998). This decrease in HMG-CoA reductase activity by tyrosine kinase
inhibitor was shown to be at the level of mRNA. Later studies also demonstrated that
HMG-CoA reductase mRNA levels could be increased by cAMP, thereby increasing the
activity of HMG-CoA reductase (Golos and Strauss 1988).
The idea that HMG-CoA reductase activity could be modified by changes in
membrane fluidity was introduced four decades ago. Berde et al. in 1977 demonstrated
that HMG-CoA reductase activity was stimulated by phospholipids (Berde, Heller et al.
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1977).

They

showed

that

microsomal

lipids

including

phosphatidylcholine,

phosphatidylethanolamine and phosphatidylserine increased HMG-CoA reductase
activity in vitro. A subsequent study done by Heusden et al. in 1984 demonstrated that a
non-specific lipid transfer protein, which transfers cholesterol and natural phospholipids
between membranes, could not change HMG-CoA reductase activity (van Heusden and
Wirtz 1984).

Contradictory to this study, the study done by Davis et al, in 1987

demonstrated that addition of rigid or fluid phospholipids to microsomal membranes
modulated HMG-CoA reductase activity in vitro (Davis and Poznansky 1987). This data
supports the idea that HMG-CoA reductase and consequently cholesterol biosynthesis
could be regulated by the fluidity or the composition of the endoplasmic reticulum
membranes. However, the nexus between membrane fluidity and HMG-CoA reductase
remains elusive.
The observation that SPF stimulates HMG-CoA reductase both in vitro and in cell
culture is very surprising.

Tormanen et al. in 1977 observed that when rat liver

microsomes were treated with cytosol from the same animals, the activity of HMG-CoA
reductase in vitro was reduced (Tormanen, Srikantaiah et al. 1977). In contrast Lehrer
et al, in 1981 had demonstrated that addition of crude rat liver cytosol to microsomes
increased the HMG-CoA reductase activity (Lehrer, Panini et al. 1981). In my studies
the amount of cytosol and also the amount of recombinant SPF protein added to these
assays is paramount. Excessive amounts of both lead to a decrease in activity, and the
exact reason is yet unknown.
The present studies demonstrate an unexpected but exciting finding: Human
supernatant protein factor, which was known to stimulate the reaction catalyzed by
squalene monooxygenase, also acts on the key rate-limiting enzyme in cholesterol
synthesis, HMG-CoA reductase (HMGR). The exact mechanism by which SPF effects
the stimulation is yet unknown, but two possible schemes can be proposed.
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Possible Schemes of Activation
SCHEME1: SPF is known to bind to phospholipids such as phosphatidylserine,
phosphatidylinositol and phosphatidylglycerol. It is possible that SPF transfers these
ligands on to endoplasmic reticulum membranes where HMG-CoA reductase is present,
and inserts these ligands into the membrane, thereby altering the properties of the
membrane and increasing the rate of the reaction catalyzed by HMG-CoA reductase.
Evidence comes from the studies Berde et al. (Berde, Heller et al. 1977) who
demonstrated that phospholipids activate the HMG-CoA reductase reaction. In addition
Davis and Poznasky in 1987 demonstrated that HMG-CoA reductase activity is
sensitive to changes in the phospholipid composition of the membrane (Davis and
Poznansky 1987). The same authors also showed that when the membrane fluidity was
increased HMG-CoA reductase activity was reduced. SPF could be transferring its lipid
ligands to the membrane and consequently decreasing the fluidity of the membrane and
stabilizing it (Fig 6.1A).
SCHEME 2: SPF protein contains a CRAL-TRIO domain believed to be involved
in lipid-binding. TRIO proteins are multi-domain proteins which have been determined
to play an important role as a guanine exchange factor and in neuronal growth
(Bateman and Van Vactor 2001). Rho GTPase activating protein (RhoGAP) has been
found to interact with HMG-CoA reductase in a yeast two hybrid system (Nagaraja and
Kandpal 2004). In addition SPF possess a GOLD (Golgi dynamics) domain, and it has
been shown that the GOLD-domain proteins can interact with other proteins and
function as double headed adapters and interact with specific protein and/or
membranes (Anantharaman and Aravind 2002). It is possible that SPF may actually be
interacting with HMG-CoA reductase in ways unknown and increasing the rate of the
reaction (Fig 6.1B).
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Figure 6.1 Possible mechanisms of the SPF-mediated activation of HMG-CoA
reductase.

A: SPF transfers its putative ligand to the membrane and thereby increases membrane

SPF

HMGCR

HMGCR

SPF

stability, causing an increase in HMG-CoA reductase activity.

STABLE MEMBRANE

UNSTABLE MEMBRANE

B: SPF directly interacts with HMG-Co A reductase at the membrane, thereby
increasing HMG-CoA reductase activity.

HMGCR

SPF

MEMBRANE
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Protein Kinase A and SPF Regulation
Protein kinases have been linked to the regulation of cholesterol synthesis and
homeostasis, and the best characterized action is that of the down-regulation of HMGCoA reductase activity by AMP-activated protein kinase (Hardie 1992) and by PKC
(Mehta, Radominska-Pandya et al. 2002). Protein kinase A (PKA) is very effective in
activating recombinant SPF in vitro and also the SPF-mediated stimulation of
cholesterol synthesis in cell culture.

PKA has not been earlier implicated in the

regulation of cholesterol synthesis, although it plays an important role in the activation of
cholesterol transport to the mitochondria for steroidogenesis (Arakane, King et al.
1997). PKA has also been implicated in the up-regulation of the low density lipoprotein
receptor (Sekar and Veldhuis 2001). PKA is a cAMP-dependent kinase and thus can
be activated by many of the adenylate-cyclase dependent signaling pathways available
to the cell. The study presented above demonstrates that SPF is activated by PKA and
suggests that the phosphorylation of this protein regulates short-term cholesterol
synthesis in cell culture.
Future Studies
Since the last decade much information has been gained on this enigmatic
protein, but the absolute mechanism of action has not been determined. It is apparent
that SPF is important for the short-term regulation of cholesterol synthesis in cell culture
and this protein affects squalene monooxygenase in vitro.

This last section of the

dissertation is dedicated to various prospective studies which would help unravel the
mystery of this protein.
We have mutated Ser289 to Ala, which in turn abolished the activity of SPF to be
activated by protein kinase A in vitro and completely abolished the SPF-mediated
stimulation of cholesterol synthesis in SPF-expressing cells.

Ser289 could also be

mutated to Glu. Because Glu carries a negative charge on its side chain carboxyl
group, it resembles phosphorylated serine, and might substitute effectively for
phosphoserine. Replacement of key amino acids with Glu has been shown to
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constitutively activate other enzymatic systems.

This replacement would give us a

definite insight to assess if Ser289 is indeed the key amino acid for the SPF-mediated
cholesterol synthesis in cell culture and in vitro.
I have also demonstrated the need for the Golgi apparatus in the SPF-mediated
stimulation of cholesterol synthesis.

The next key step would be to create green

fluorescent tagged protein (GFP) versions of SPF and assess the localization of this
protein in cell culture using confocal microscopy or real-time imagery. This strategy
would help in visualizing the intracellular localization of this protein and give us a further
perspective of this protein.
In this study I demonstrate a unique finding: SPF stimulates the enzymes
squalene monooxygenase and HMG-CoA reductase and thereby increase cholesterol
synthesis in cell culture. The activation of this protein by PKA phosphorylation suggests
that cholesterol synthesis can be rapidly modulated in response to external stimuli by
changes in cAMP levels. To what extent this system operates in vivo to modulate
cholesterol synthesis is an important area for future investigation.

Copyright © Vishwesh Mokashi 2004
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